Drugs Made In America Acquisition II Corp. (DMII) Stock Statistics & Valuation Metrics

Drugs Made In America Acquisition II Corp. has a market cap or net worth of $642.73M. The enterprise value is $6.43M.

Drugs Made In America Acquisition II Corp. has 63,700,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Drugs Made In America Acquisition II Corp.’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is -0.26%.

The current PE Ratio of Drugs Made In America Acquisition II Corp. is 0.6. Drugs Made In America Acquisition II Corp.’s PEG ratio is -0.00914.

In the last 12 months, Drugs Made In America Acquisition II Corp. had revenue of 0.00 and earned 4.19M in profits. Earnings per share was 0.16.

In the last 12 months, operating cash flow was -1.11M and capital expenditures -4.00, giving a free cash flow of -1.11M billion.

Drugs Made In America Acquisition II Corp. pays an annual dividend of ―, resulting in a dividend yield of ―

Drugs Made In America Acquisition II Corp. upcoming earnings date is ―, ―.

Drugs Made In America Acquisition II Corp. as a current ratio of 0.09, with Debt / Equity ratio of 0.09%

In the past 12 months, Drugs Made In America Acquisition II Corp. has paid 0.00 in taxes.

Drugs Made In America Acquisition II Corp. EV to EBITDA ratio is -101.15, with an EV/FCF ratio of -129.19.

Drugs Made In America Acquisition II Corp. has $347.72K in cash and marketable securities with $450.00K in debt, giving a net cash position of -$102.28K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Drugs Made In America Acquisition II Corp. is ―, which is 11.43% higher than the current price. The consensus rating is ―